恩替卡韦治疗慢性乙型肝炎53例疗效分析

目的：评价恩替卡韦治疗慢性乙型肝炎（CHB）12个月的疗效和安全性.方法：选择CHB患者53例给予恩替卡韦0.5 mg/d抗病毒治疗12个月,53例患者治疗前乙型肝炎病毒（HBV）DNA载量分为107～109、105～106、104 copies/L进行分层,分别观察服药后1、3、6、12个月时HBV DNA载量,丙氨酸氨基转氨酶（ALT）、天门冬氨酸氨基转氨酶（AST）变化情况.结果：恩替卡韦对治疗前HBV DNA载量分别为107～109、105～106、104均具有较强的抑制作用;治疗后随着时间推移HBV DNA载量下降越明显,治疗前HBV DNA载量越低服药后HBV DNA载量越快达到正常值,治疗前后差异均有统计学意义（P＜0.05～P＜0.01）.恩替卡韦抑制HBV DNA的同时伴随ALT、AST的下降,治疗前HBV DNA载量越低,治疗后12个月ALT、AST复常率越高,治疗前后差异均有统计学意义（P＜0.05～P＜0.01）.结论：恩替卡韦对CHB患者HBV有很强的抑制作用,在抑制病毒复制的同时能改善肝功能.

Efficacy analysis of entecavir to 53 chronic hepatitis B patients

Objective ： To evaluate the efficacy and safety of entecavir to chronic hepatitis B （CHB）. Methods： Fifty-three patients who had been treated with enteeavir（0.5 mg/d） for 12 months were divided into three groups：HBV DNA 107 - 109 copies/L, HBV DNA 105 - 106 copies/L, HBV DNA 104 copies/L. Fasting venous blood were collected from each patient after treatment of 1,3,6 and 12 months for detection of hepatitis B viral（HBV） load DNA, alanine aminotransferase （ALT）, aspartate transaminase （AST）. Results： As the duration of treatment, HBV DNA, ALT, and AST all decreased significantly （ P 〈 0.05 ）. three markers were all significantly lower after 1 month treatment than before treatment. Three markers were also significantly lower after 3 month treatment than that after 1 month treatment. As well as, three markers were significantly lower after 12 month treatment than that after 3 month treatment. Additionally, compared with high viral loads group, HBV DNA, ALT, and AST converted negative earlier in lower viral loads group （ P 〈 0.05 to P 〈 0.01 ）. Conclusions：Enteeavir can suppress HBV replication and improve liver function of the patients.